JP7721517B2 - Ｃｆｔｒ活性の欠損が介在する状態を治療するための５員ヘテロアリールアミノスルホンアミド - Google Patents

Ｃｆｔｒ活性の欠損が介在する状態を治療するための５員ヘテロアリールアミノスルホンアミド

Info

Publication number
JP7721517B2
JP7721517B2 JP2022527081A JP2022527081A JP7721517B2 JP 7721517 B2 JP7721517 B2 JP 7721517B2 JP 2022527081 A JP2022527081 A JP 2022527081A JP 2022527081 A JP2022527081 A JP 2022527081A JP 7721517 B2 JP7721517 B2 JP 7721517B2
Authority
JP
Japan
Prior art keywords
alkyl
compound
substituted
occurrences
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022527081A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023500408A5 (https=
JP2023500408A (ja
Inventor
ジュンカイ リャオ
マーク マンソン
ジョンリー ガオ
グレゴリー ハールバト
シルヴィー バルツァー
ベルトラン ヴィヴェ
ブライアン フリード
ハンス ペーター ネスラー
ヘレン ヨーマン
イングリッド メシャン
マルティン スムルチナ
ニーナ マ
シルヴァン ルブルトン
ライアン ハルトゥング
ウィリアム ワイアー
スカンティニ テュライラトナム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of JP2023500408A publication Critical patent/JP2023500408A/ja
Publication of JP2023500408A5 publication Critical patent/JP2023500408A5/ja
Priority to JP2025126773A priority Critical patent/JP2025160375A/ja
Application granted granted Critical
Publication of JP7721517B2 publication Critical patent/JP7721517B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/50—Nitrogen atoms bound to hetero atoms
    • C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/222—Amides of phosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
    • C07F9/6539—Five-membered rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022527081A 2019-11-12 2020-11-12 Ｃｆｔｒ活性の欠損が介在する状態を治療するための５員ヘテロアリールアミノスルホンアミド Active JP7721517B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025126773A JP2025160375A (ja) 2019-11-12 2025-07-30 Ｃｆｔｒ活性の欠損が介在する状態を治療するための５員ヘテロアリールアミノスルホンアミド

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962934293P 2019-11-12 2019-11-12
US62/934,293 2019-11-12
PCT/US2020/060180 WO2021097057A1 (en) 2019-11-12 2020-11-12 5-membered heteroarylaminosulfonamides for treating conditions mediated by deficient cftr activity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025126773A Division JP2025160375A (ja) 2019-11-12 2025-07-30 Ｃｆｔｒ活性の欠損が介在する状態を治療するための５員ヘテロアリールアミノスルホンアミド

Publications (3)

Publication Number Publication Date
JP2023500408A JP2023500408A (ja) 2023-01-05
JP2023500408A5 JP2023500408A5 (https=) 2023-11-20
JP7721517B2 true JP7721517B2 (ja) 2025-08-12

Family

ID=73740547

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022527081A Active JP7721517B2 (ja) 2019-11-12 2020-11-12 Ｃｆｔｒ活性の欠損が介在する状態を治療するための５員ヘテロアリールアミノスルホンアミド
JP2025126773A Pending JP2025160375A (ja) 2019-11-12 2025-07-30 Ｃｆｔｒ活性の欠損が介在する状態を治療するための５員ヘテロアリールアミノスルホンアミド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025126773A Pending JP2025160375A (ja) 2019-11-12 2025-07-30 Ｃｆｔｒ活性の欠損が介在する状態を治療するための５員ヘテロアリールアミノスルホンアミド

Country Status (17)

Country Link
US (1) US20240002374A1 (https=)
EP (1) EP4058439A1 (https=)
JP (2) JP7721517B2 (https=)
KR (1) KR20220115829A (https=)
CN (1) CN115003659B (https=)
AU (1) AU2020384279A1 (https=)
BR (1) BR112022009185A2 (https=)
CA (1) CA3158057A1 (https=)
CL (1) CL2022001245A1 (https=)
CO (1) CO2022007953A2 (https=)
EC (1) ECSP22046050A (https=)
IL (1) IL292966A (https=)
JO (1) JOP20220105A1 (https=)
MX (1) MX2022005809A (https=)
PE (1) PE20221461A1 (https=)
PH (1) PH12022551139A1 (https=)
WO (1) WO2021097057A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019222758B2 (en) 2018-02-15 2022-07-07 Vertex Pharmaceuticals Incorporated Macrocycles as modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions thereof, their use in the treatment of cystic fibrosis, and process for making them
TWI848092B (zh) 2019-04-03 2024-07-11 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白調節劑
TWI867024B (zh) 2019-08-14 2024-12-21 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白之調節劑
CA3150162A1 (en) 2019-08-14 2021-02-18 Vertex Pharmaceuticals Incorporated Crystalline forms of cftr modulators
TWI899097B (zh) 2019-08-14 2025-10-01 美商維泰克斯製藥公司 製備cftr調節劑之方法
EP4058434A1 (en) 2019-11-12 2022-09-21 Genzyme Corporation 6-membered heteroarylaminosulfonamides for treating diseases and conditions mediated by deficient cftr activity
WO2022076628A1 (en) * 2020-10-07 2022-04-14 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
AU2021397294A1 (en) 2020-12-10 2023-07-06 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
CN113480416B (zh) * 2021-07-12 2023-03-21 重庆大学 一种芳基酮的制备方法
KR20240168370A (ko) 2022-03-30 2024-11-29 이시하라 산교 가부시끼가이샤 피리다지논계 화합물 또는 그의 염 및 그들을 함유하는 유해 생물 방제제
CN114835655A (zh) * 2022-04-14 2022-08-02 河南师范大学 一种合成光学活性三氟甲基丙烯酸酯类化合物的方法
EP4611742A1 (en) 2022-10-31 2025-09-10 Sionna Therapeutics Inc. Methods of treating cftr-mediated diseases or disorders
WO2025017207A1 (en) * 2023-07-20 2025-01-23 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Inhibitors of smndc1 and their therapeutic use
WO2025076235A1 (en) 2023-10-04 2025-04-10 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007504255A (ja) 2003-09-06 2007-03-01 バーテックス　ファーマシューティカルズ　インコーポレイテッド Ａｔｐ結合カセットトランスポーターの調節因子
JP2017074057A (ja) 2011-06-10 2017-04-20 メディミューン，エルエルシー 抗シュードモナス属（Ｐｓｅｕｄｏｍｏｎａｓ）Ｐｓｌ結合分子およびその使用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992015570A1 (en) * 1991-03-07 1992-09-17 Hisamitsu Pharmaceutical Co., Inc. Novel diphenylthyazole derivative
US5856347A (en) * 1994-11-29 1999-01-05 Hisamitsu Pharmaceutical Co., Inc. Antibacterial preparation or bactericide comprising 2-aminothiazole derivative and/or salt thereof
JP2005510508A (ja) * 2001-11-08 2005-04-21 藤沢薬品工業株式会社 アデノシンアンタゴニストとしてのチアゾールピリダジノン類
WO2016183173A1 (en) * 2015-05-12 2016-11-17 Avista Pharma Solutions Antiparasitic compounds
US10138227B2 (en) * 2016-06-03 2018-11-27 Abbvie S.Á.R.L. Heteroaryl substituted pyridines and methods of use
TW201811766A (zh) * 2016-08-29 2018-04-01 瑞士商諾華公司 N-(吡啶-2-基)吡啶-磺醯胺衍生物及其用於疾病治療之用途
EP4611742A1 (en) * 2022-10-31 2025-09-10 Sionna Therapeutics Inc. Methods of treating cftr-mediated diseases or disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007504255A (ja) 2003-09-06 2007-03-01 バーテックス　ファーマシューティカルズ　インコーポレイテッド Ａｔｐ結合カセットトランスポーターの調節因子
JP2017074057A (ja) 2011-06-10 2017-04-20 メディミューン，エルエルシー 抗シュードモナス属（Ｐｓｅｕｄｏｍｏｎａｓ）Ｐｓｌ結合分子およびその使用

Also Published As

Publication number Publication date
MX2022005809A (es) 2022-06-08
WO2021097057A1 (en) 2021-05-20
PE20221461A1 (es) 2022-09-21
JP2025160375A (ja) 2025-10-22
EP4058439A1 (en) 2022-09-21
KR20220115829A (ko) 2022-08-18
JOP20220105A1 (ar) 2023-01-30
AU2020384279A1 (en) 2022-05-26
IL292966A (en) 2022-07-01
CL2022001245A1 (es) 2023-03-10
CN115003659A (zh) 2022-09-02
CN115003659B (zh) 2026-04-21
BR112022009185A2 (pt) 2022-07-26
CO2022007953A2 (es) 2022-09-09
US20240002374A1 (en) 2024-01-04
ECSP22046050A (es) 2022-08-31
CA3158057A1 (en) 2021-05-20
PH12022551139A1 (en) 2023-07-17
JP2023500408A (ja) 2023-01-05

Similar Documents

Publication Publication Date Title
JP7721517B2 (ja) Ｃｆｔｒ活性の欠損が介在する状態を治療するための５員ヘテロアリールアミノスルホンアミド
US12583824B2 (en) 6-membered heteroarylaminosulfonamides for treating diseases and conditions mediated by deficient CFTR activity
JP2022513959A5 (https=)
JP2022513959A (ja) 大環状化合物及び疾患の処置におけるそれらの使用
US20240279220A1 (en) Indole compounds and methods of use
JP2024512428A (ja) 抗ウイルス化合物
WO2020161623A1 (en) N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease
US20220117945A1 (en) Isoxazole carboxamide compounds and uses thereof
WO2025129104A1 (en) Compounds, compositions, and methods of using thereof
EA051473B1 (ru) 5-членные гетероариламиносульфонамиды и способы их применения
OA21686A (en) 5-Membered heteroarylamino-sulfonamides for treating conditions mediated by deficient CFTR activity.
AU2023283549A1 (en) Compounds, compositions, and methods of using thereof
RU2804139C2 (ru) Макроциклические соединения и их применение в лечении заболевания
WO2024054840A1 (en) Macrocyclic compounds, compositions, and methods of using thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220822

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230706

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231109

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231109

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240912

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241003

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241223

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250411

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250605

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250704

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250730

R150 Certificate of patent or registration of utility model

Ref document number: 7721517

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150